Lorazepam

Generic Name: Lorazepam

Brand Names: Ativan, Loreev

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₀Cl_₂N_₂O_₂

CAS Number: 846-49-1

Unique Ingredient Identifier: O26FZP769L

Background: Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication: Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
...

Associated Conditions: Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus

Associated Therapies: Anesthetic premedication therapy

Clinical Trials

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Therapeutic Hypothermia With Propofol in Survival and Neurological Prognoses After Cardiac Arrest

Phase 4

Conditions: Cardiac Arrest
Hypothermia

Interventions: Drug: Propofol
Drug: Lorazepam

First Posted Date: 2015-02-20

Last Posted Date: 2016-03-29

Lead Sponsor: Far Eastern Memorial Hospital

Target Recruit Count: 30

Registration Number: NCT02367755

Locations: 🇨🇳
Far Eastern Memorial Hospital, New Taipei City, Taiwan

The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism

Not Applicable

Completed

Conditions: Opiate Addiction

Interventions: Drug: Naltrexone
Drug: Clonidine
Drug: Lorazepam

First Posted Date: 2015-02-12

Last Posted Date: 2015-02-12

Lead Sponsor: Vilnius University

Target Recruit Count: 60

Registration Number: NCT02362256

Locations: 🇱🇹
Republic Vilnius University Hospital, Vilnius, Lithuania

Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan

Phase 3

Completed

Conditions: Status Epilepticus

Interventions: Drug: Lorazepam

First Posted Date: 2014-09-12

Last Posted Date: 2019-02-18

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT02239380

Locations: 🇯🇵
Aichi Children's Health and Medical Center, Obu-shi, Aichi, Japan
🇯🇵
National Hospital Organization Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan
🇯🇵
Nakamura Memorial Hospital, Sapporo, Hokkaido, Japan

and more 17 locations

Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly

Phase 3

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: etifoxine
Drug: lorazepam

First Posted Date: 2014-05-26

Last Posted Date: 2016-07-27

Lead Sponsor: Biocodex

Target Recruit Count: 31

Registration Number: NCT02147548

Locations: 🇫🇷
Centre d'Investigation Clinique, CIC 1403 INSERM/CHRU, Lille, France

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

Phase 3

Terminated

Conditions: Epilepsia Partialis Continua
Kojewnikov's Epilepsy
Epilepsy

Interventions: Drug: Clobazam
Drug: Clonazepam
Drug: Lorazepam

First Posted Date: 2014-05-09

Last Posted Date: 2018-05-09

Lead Sponsor: The Cooper Health System

Target Recruit Count: 7

Registration Number: NCT02134366

Locations: 🇺🇸
Cooper Universtiy Hospital, Camden, New Jersey, United States

Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Lorazepam

First Posted Date: 2013-11-26

Last Posted Date: 2014-03-03

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT01994668

Locations: 🇯🇵
Pfizer Investigational Site, Hachioji-shi, Tokyo, Japan

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Cancers

Interventions: Drug: Placebo
Drug: Lorazepam
Drug: Haloperidol decanoate
Behavioral: Questionnaires

First Posted Date: 2013-09-24

Last Posted Date: 2024-07-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 93

Registration Number: NCT01949662

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sedative Premedication: Efficacy On Patient Experience

Phase 3

Completed

Conditions: Perioperative Anxiety

Interventions: Other: no premedication
Drug: Placebo (microcrystalline celluloses)
Drug: Lorazepam

First Posted Date: 2013-07-17

Last Posted Date: 2015-04-21

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 1200

Registration Number: NCT01901003

Locations: 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France

Characterizing and Predicting Drug Effects on Cognition

Phase 4

Completed

Conditions: Cognitive Deficits

Interventions: Drug: Lorazepam
Other: Placebo
Drug: Topiramate 200mg
Drug: Topiramate 150mg
Drug: Topiramate 100mg

First Posted Date: 2013-06-28

Last Posted Date: 2019-12-17

Lead Sponsor: University of Minnesota

Target Recruit Count: 60

Registration Number: NCT01889602

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy